QIAGEN Reports Robust Q2 Earnings and Uplifts Full-Year Revenue Forecast

RTTNews — Biotechnology firm QIAGEN N.V. (QGEN) announced its financial performance for the second quarter of 2025, accompanied by an upward revision of its annual sales projections. In the quarter, net sales increased by 7% year-over-year to reach $534 million, with a 6% rise when adjusted for currency fluctuations. The company's net income shifted from a loss of $183 million in the same period last year to a profit of $96 million. Earnings per share improved from a loss of $0.82 to $0.44. On an adjusted basis, net income grew by 8% to $132 million, and adjusted diluted earnings per share rose by 9% to $0.60. QIAGEN now expects full-year 2025 net sales to increase by 4% to 5% at constant exchange rates, an upgrade from its previous forecast of approximately 4%. The firm also anticipates core business sales to grow between 5% and 6% CER, excluding discontinued products. On the New York Stock Exchange, QGEN closed Tuesday at $49.95, a decline of $0.30 or 0.60%. The opinions expressed are those of the author and do not necessarily reflect the views of Nasdaq, Inc.